PCSK9抑制剂在冠状动脉粥样硬化性心脏病治疗中的应用(4)
[13]Zhang DW，Lagace TA，Garuti R，et al.Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation[J].Journal of Biological Chemistry，2007，282(25)：18602-18612.
[14]Yamamoto T，Lu C，Ryan RO.A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor[J].Journal of Biological Chemistry，2011，286(7)：5464-5470.
[15]Surdo PL，Bottomley MJ，Calzetta A，et al.Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH[J].Embo Reports，2011，12(12)：1300-1305.
[16]Rashid H，Meredith IT，Nasis A.PCSK9 Monoclonal Antibodies in 2016：Current Status and Future Challenges[J].Heart Lung&Circulation，2017，26(8)：786-798.
[17]Sabatine MS，Giugliano RP，Wiviott SD，et al.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J].N Engl J Med，2015，372(16)：1489-1499.
[18]Schwartz GG，Steg PG，Szarek M，et al.Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome[J].N Engl J Med，2018，379(22)：2097-2107.
[19]Nicholls SJ，Puri R，Anderson T，et al.Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients：The GLAGOV Randomized Clinical Trial[J].JAMA，2016，316(22)：2373-2384.
[20]Sabatine MS，Giugliano RP，Keech AC，et al.Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease[J].N Engl J Med，2017，376(18)：1713-1722.
收稿日期：2019-5-10;修回日期：2019-5-20
編辑/肖婷婷, http://www.100md.com(陈涛 孙晶琳 张健)
[14]Yamamoto T，Lu C，Ryan RO.A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor[J].Journal of Biological Chemistry，2011，286(7)：5464-5470.
[15]Surdo PL，Bottomley MJ，Calzetta A，et al.Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH[J].Embo Reports，2011，12(12)：1300-1305.
[16]Rashid H，Meredith IT，Nasis A.PCSK9 Monoclonal Antibodies in 2016：Current Status and Future Challenges[J].Heart Lung&Circulation，2017，26(8)：786-798.
[17]Sabatine MS，Giugliano RP，Wiviott SD，et al.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J].N Engl J Med，2015，372(16)：1489-1499.
[18]Schwartz GG，Steg PG，Szarek M，et al.Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome[J].N Engl J Med，2018，379(22)：2097-2107.
[19]Nicholls SJ，Puri R，Anderson T，et al.Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients：The GLAGOV Randomized Clinical Trial[J].JAMA，2016，316(22)：2373-2384.
[20]Sabatine MS，Giugliano RP，Keech AC，et al.Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease[J].N Engl J Med，2017，376(18)：1713-1722.
收稿日期：2019-5-10;修回日期：2019-5-20
編辑/肖婷婷, http://www.100md.com(陈涛 孙晶琳 张健)